Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Teijin Pharma’s Osteoporosis Med Ostabalo Now Available in Japan
January 31, 2023
- AnGes to Start Japan PII for NF-κB Decoy Oligo for Lower Back Pain
January 31, 2023
- Rexulti Filed for Major Depressive Disorder in Japan: Otsuka
January 31, 2023
- Shionogi Logs Record Profits as Xocova Nets 100 Billion Yen from Govt Purchase: April-December
January 31, 2023
- UCB Files Bimzelx for Label Expansion in Psoriatic Arthritis and More
January 31, 2023
- Lecanemab Earns Priority Review in Japan, Eisai Aims for Approval by Year-End
January 31, 2023
- Takeda to Transfer MS Med Copaxone to Teva JV, 1st Patented Drug under 2020 Pact
January 30, 2023
- Estimated 21,528 Patients Given Xocova as of Jan. 22: Shionogi
January 30, 2023
- Lecanemab Application Accepted for Review in Europe; FY2023 Approval Eyed
January 30, 2023
- NanoCarrier to Shift Biz Model to mRNA Out-Licensing, Joins Forces with Axcelead
January 27, 2023
- Torii Acquires Japan Rights for Nogra Pharma’s Acne Drug
January 27, 2023
- Enhertu Wins EU Approval for HER2 Low Breast Cancer
January 27, 2023
- Shipments of All 6 Argatroban Products Suspended or Restricted in Japan
January 26, 2023
- Multifunctional Peptide Conjugate Meets Criteria in Joint Research: PeptiDream/Santen
January 26, 2023
- Ono/KSQ Therapeutics Tie Up for Cancer Drug Discovery
January 26, 2023
- Takeda Gets Rights to Hutchmed’s Colorectal Cancer Med Outside China
January 25, 2023
- Astellas to Divest Antifungal Micafungin to Sandoz for Up to US$75 Million Upfront
January 25, 2023
- Moderna, NCGM Ink MOU to Push mRNA-Based Healthcare
January 24, 2023
- J-Pharma’s Biliary Tract Cancer Med Hits Mark in Japan PII Study
January 24, 2023
- Alzheimer’s Drug Leqembi Now Available in US: Eisai/Biogen
January 24, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…